{"id":"NCT02722044","sponsor":"Momenta Pharmaceuticals, Inc.","briefTitle":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","officialTitle":"An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2017-02-21","completion":"2017-02-21","firstPosted":"2016-03-29","resultsPosted":"2018-05-01","lastUpdate":"2018-05-16"},"enrollment":33,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"M923","otherNames":["Adalimumab"]},{"type":"DEVICE","name":"Autoinjector","otherNames":[]}],"arms":[{"label":"All Study Participants","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)","primaryOutcome":{"measure":"Usability of the Auto-injector (AI) at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"M923 40 mg","deltaMin":8.15,"sd":2.049}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Injection site pain","Injection site erythema","Injection site bruising","Injection site swelling","Injection site coldness"]}}